Navigation Links
InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Date:3/15/2013

TEL-AVIV, Israel, March 15, 2013 /PRNewswire/ --

InspireMD's Carotid Embolic Protection Stent, based on InspireMD's proprietary MicroNet[TM] mesh technology, is designed to provide procedural and post-procedural distal embolic protection in Carotid Artery Stenting(CAS) procedures and there by reduce risk of stroke events.

InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ Embolic Protection Stent (EPS), announced today that the Company received CE mark approval this morning for its self-expanding Nitinol carotid EPS.  This carotid embolic protection stent is based on the proprietary MicroNet[TM] mesh protection platform technology used to treat heart attack patients with InspireMD's commercially available coronary EPS stents, MGuard[TM] and MGuard Prime[TM].  

When treating carotid arterial disease, close to half of Carotid Artery Stenting (CAS) procedures cause distal embolic events that may lead to stroke within 30 days.  The InspireMD Carotid Embolic Protection Stent (EPS) is wrapped with a MicroNet[TM] mesh to prevent embolic events during and post CAS procedure.  The MicroNet[TM] is designed to hold plaque and thrombus in place against the wall of the blocked artery, preventing debris from falling into the bloodstream and causing a potentially fatal downstream blockage or stroke.

In coronary procedures, InspireMD's EPS technology has already shown improvements through the MASTER trial findings that revealed a statistically and clinically significant acute advantage of MGuard EPS with regard to ST segment resolution. As a resul
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
2. InspireMD Reports Results for Period Ended Dec. 31, 2012
3. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
4. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
5. InspireMD Reports Results For Period Ending Sept. 30, 2012
6. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
7. InspireMD to Present at Harvard Investors Group on June 27 in New York
8. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
9. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
10. InspireMD Announces First Quarter 2012 Financial Results
11. Cardium Receives ISO Certification for Excellagen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
(Date:4/16/2014)... the marvel of the embryo. It begins as a glob ... multiply to become the cells of our lungs, muscles, nerves ... Now, in a feat of reverse tissue engineering, Stanford University ... allows embryonic cells to proliferate and transform into all of ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... to fight invasive fungal infections, which kill about 1.5 million people ... action of amphotericin, an antifungal drug that has been in use ... as toxic to human cells as it is to the microbes ...
Breaking Medicine News(10 mins):Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... Ind. - While biometric equipment is gaining popularity in ... to buildings, industries are finding that many users believe ... germs that could cause illness. , But a Purdue ... surfaces of devices that scan fingerprints or hand geometry ...
... In addition to the Spa, Six Signature Spa Suites Make Their ... Moon, the Caribbean,s Most Complete ... of Jamaica, the Honourable Bruce Golding, cut the ribbon to signal,the ... The Oct. 6 event marked the conclusion of a 15-month ...
... Department of,Veterans Affairs (VA) will augment its world-class ... grant received today from the Lilly Endowment,Inc. ... the Richard L. Roudebush VA Medical Center to ... from Iraq and Afghanistan and other,projects, including a ...
... news on research and advocacy reaches niche communities on ... RESTON, Va., Oct. 10 Voxant, the New ... 43,000 news videos,articles, and images dedicated to health news, ... Awareness month, and Voxant,has over 1,500 news assets that ...
... nutrition, physical activity and grieving programs, PITTSBURGH, ... than $580,000 in grants to four non-profit organizations,through ... will be used for,nutrition and physical activity programs ... program in Centre, Huntingdon and Mifflin counties. ...
... announced today that,their client, Critical Access HealthCare LLC ... critical access hospital in Borger,Texas. Ziegler Healthcare Consulting ... Under the terms of the Sept. 30 ... Golden Plains Community Hospital -- except for the ...
Cached Medicine News:Health News:Biometric sensors no dirtier than doorknobs, study finds 2Health News:Biometric sensors no dirtier than doorknobs, study finds 3Health News:Fern Tree, The Spa at Half Moon, Jamaica's Premier Spa, Opens With Ceremonial Ribbon Cutting 2Health News:Fern Tree, The Spa at Half Moon, Jamaica's Premier Spa, Opens With Ceremonial Ribbon Cutting 3Health News:Lilly Grant to VA Will Enhance Services for Returning Combat Veterans 2Health News:Voxant, the New Media Network, Distributes More Than 43,000 Health News Videos, Articles and Images 2Health News:Voxant, the New Media Network, Distributes More Than 43,000 Health News Videos, Articles and Images 3Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 2Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 3Health News:The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations 4Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 2Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 3Health News:Ziegler Client, Critical Access HealthCare LLC, Acquires Texas Hospital 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: